Pharma News

Swiss pharma giant Roche has approached the Supreme Court of India to challenge a recent Delhi High Court ruling that allowed Natco Pharma to launch a generic version of Risdiplam, Roche’s breakthrough treatment for spinal muscular atrophy (SMA).

In a fresh regulatory controversy, Indian authorities have accused Balaji Amines, a major chemical manufacturer, of producing pharmaceutical-grade propylene glycol (PG) without holding a valid drug manufacturing licence.

Johnson & Johnson (J&J) has announced plans to separate its orthopedics unit into a standalone company, while simultaneously raising its 2025 full-year sales guidance.

Bayer, via its subsidiary Viralgen (acquired through AskBio in 2020), is aggressively advancing a gene and cell therapy (CGT) portfolio targeting Parkinson’s disease, oncology, cardiovascular, rare conditions, and more.

Aspen Pharmacare announced that it has obtained regulatory approval in South Africa to market Lilly’s Mounjaro (tirzepatide) for chronic weight management, expanding the indication beyond its prior authorization for Type 2 diabetes.

Mumbai, October 13, 2025 — Bristol Myers Squibb (BMS) has launched its novel cardiovascular drug Mavacamten, under the brand name Kopozgo, in India.

Eli Lilly’s once-daily oral GLP-1, orforglipron, outperformed Novo Nordisk’s oral semaglutide (Rybelsus) in a head-to-head diabetes study, reinforcing Lilly’s bid to lead in pills as well as injectables.

India’s largest drugmaker underscores that precision—designing drugs to reduce side effects and improve delivery for very specific patient needs—beats scattershot expansion.

India’s largest drugmaker Sun Pharma has carved out its niche by focusing on unmet patient needs rather than chasing every new market segment, according to founder and executive chairman Dilip Shanghvi.

On September 5, NHU announced progress at its joint venture with Sinopec, Ningbo Zhenhai Refining & Chemical NHU Biotechnology Co., which has successfully produced qualified output from its 180,000 t/year liquid methionine project.

AstraZeneca plans to submit baxdrostat for regulatory review by the end of 2025, aiming for potential approvals in 2026 starting in the U.S. and EU.

Cytokinetics’ aficamten improved symptoms and cardiopulmonary performance more than metoprolol in a 175-patient head-to-head study of obstructive hypertrophic cardiomyopathy (oHCM), with detailed data unveiled at the ESC Congress (Madrid).

The U.S. FDA approved Sanofi’s BTK inhibitor Wayrilz (rilzabrutinib) to treat adult persistent or chronic immune thrombocytopenia (ITP) who failed prior therapies—a milestone from Sanofi’s $3.7B Principia acquisition.

Glenmark Pharmaceuticals has announced a voluntary recall in the US, pulling more than 88,000 bottles of Carvedilol (a high blood pressure drug) and 22,656 bottles of Theophylline (used for COPD) from the market.

A recent report from India’s Parliamentary Committee on Petitions warns that a large proportion of cancer medicines are still not subject to official price ceilings, leaving many treatments unaffordable for patients.

Danish pharma giant Novo Nordisk has confirmed the theft of six batches of its products—including insulin brands Ryzodeg and Fiasp, and weight-loss drug Wegovy—during transit from its Bhiwandi hub to several Indian cities.

On August 7, 2025, the European Food Safety Authority (EFSA) announced that oxygen (E 948) and hydrogen (E 949) remain safe as food additives across all food categories, including products for infants and young children.

On August 11, 2025, the European Food Safety Authority (EFSA) announced its expert panel has found no safety concerns for Vitamin E polyethylene glycol succinate (TPGS) as a food additive at proposed use levels.

India’s pharmaceutical sector is calling on the US government to exclude generic drug imports from a sweeping national security investigation that could trigger major supply disruptions and price spikes.

Haryana’s Narcotics Control Bureau is seeing unprecedented public backing in its ongoing battle against drugs, according to Director General O P Singh.